Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma

BMC Cancer

Table 1 Patient demographics and characteristics

Patient No.	ECOG PS	Histological subtype	Stage	Primary site	Metastatic site	Previous DOX chemotherapy	Response	PFS (Months)
1	0	Epithelioid sarcoma	IV	Extremities	Lung and bone	Yes	PR	6
2	1	Epithelioid sarcoma	IV	Extremities	Lung and lymph nodes	Yes	PR	11
3	1	Epithelioid sarcoma	IV	Extremities	Lung and bone	Yes	PR	6
4	0	Epithelioid sarcoma	IV	Extremities	Bone	Yes	SD	9
5	1	Epithelioid sarcoma	IV	Extremities	Lung	Yes	PD	1.5
6	1	Angiosarcoma	IV	Extremities	Bone	Yes	CR	12
7	0	Angiosarcoma	IV	Extremities	Lung	Yes	SD	8
8	0	Angiosarcoma	IV	Extremities	Lung	Yes	PR	7
9	0	Rhabdomyosarcoma	IV	Head	Lung and Soft tissue	Yes	PR	9
10	0	Rhabdomyosarcoma	IV	Trunk	Bone	Yes	SD	6
11	0	Rhabdomyosarcoma	IV	Extremities	Lung	Yes	PD	3
12	1	UPS	IV	Extremities	Lung	Yes	SD	6
13	0	UPS	IV	Pelvis	Lung	Yes	PD	1.3
14	1	Fibrosarcoma	IV	Trunk	Lung	Yes	PR	9
15	0	Fibrosarcoma	IV	Extremities	Lung	Yes	PD	1
16	0	Leiomyosarcoma	IV	Extremities	Lung	Yes	PD	2
17	1	PNET	IV	Trunk	Lung	Yes	SD	3

Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, UPS Undifferentiated pleomorphic sarcoma, PNET Primitive neuroectodermal tumor, DOX Doxorubicin-based, PR Partial response, SD Stable disease, PD Progressive disease, CR Complete response. PFS Progression-free survival

ISSN: 1471-2407